Raphael J. Landovitz, M.D., M.Sc.
Co-Director, Combination Prevention Core
|Address||Center for Clinical AIDS Research & Education
David Geffen School of Medicine at UCLA
9911 W. Pico Blvd, Suite 980
Los Angeles, CA 90035
Raphael Landovitz, MD, MSc, completed his training at Princeton University and Harvard Medical School, Brigham and Women’s Hospital and Massachusetts General Hospital. He served as Medical Co-Director of the Vietnam-CDC-Harvard Medical School-AIDS-Partnership (VCHAP), helping to train Vietnamese physicians in HIV care and treatment. Dr. Landovitz relocated to Los Angeles in 2006, and is Currently Associate Professor of Medicine at the UCLA Center for Clinical AIDS Research & Education. He has led combination prevention intervention studies and projects using Post-exposure (PEP) and Pre-exposure (PrEP) strategies for MSM, as well as being part of leadership groups of the DAIDS-funded AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and the Adolescent Trials Network (ATN). He is the principal investigator of a multisite PrEP demonstration project in Los Angeles County, and the study chair of a Phase 2 study of long-acting injectable PrEP. His research agenda focuses on the optimization of the use of antiretroviral medications for both HIV treatment and HIV prevention. He was awarded the John Carey Young Investigator Award by the ACTG in 2010.
M.Sc., Clinical Research, University of California, Los Angeles, CA, US
Fellowship, Infectious Disease/HIV, Massachusetts General Hospital / Brigham and Women’s Hospital, Boston, MA, US
Residency, Internal Medicine, Brigham and Women’s Hospital, Boston, MA, US
M.D., Medicine, Harvard University, Boston, MA, US
B.A., Chemistry, Princeton University, Princeton, NJ, US
Research and Interests:
HIV/AIDS, biomedical interventions, infectious diseases